News for BioXcel Therapeutics, Inc. (BTAI)

Equity Insider News Commentary

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[578203]**

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates

Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc.

**media[560095]**

Data to support potential sNDA submission for label expansion of IGALMI® in the home setting Topline data expected in second half of 2025 NEW

North Carolina-based Chimerix, Inc. (CMRX) is up over 69 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the ”œCompany”) ( BTAI), a biopharmaceutical company utilizing artificial

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Texas-based Interactive Strength Inc. (TRNR) is up over 30 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Significant Transaction by ARMISTICE CAPITAL, LLC (Trades, Portfolio) On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a noteworthy tra

NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today

**media[532725]**

Shares of Twilio Inc. TWLO rose sharply in today's pre-market trading after the company provided preliminary financial results for the fourth quarter. After th...

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BioXcel Therapeutics stock hits 52-week low at $0.35

BioXcel Therapeutics announces pricing of public offering at $0.48 per share, grossing $7 million.